Pneumocystis Pneumonia in Immunocompromised Patients

Pneumocystis pneumonia is a life-threatening fungal infection predominantly caused by Pneumocystis jirovecii in patients whose immune defences are impaired by conditions such as HIV infection, haematological malignancy, solid organ transplantation, autoimmune disease or prolonged corticosteroid use. The organism resides in the alveolar spaces, where it triggers a diffuse interstitial pneumonitis characterised by hypoxaemia, nonproductive cough and radiographic ground-glass opacities. In the era of modern antiretroviral therapy and targeted immunosuppression, incidence among people living with HIV has fallen dramatically, but the burden remains high in non-HIV cohorts. Delayed diagnosis, owing to nonspecific clinical features and reliance on invasive sampling, contributes to elevated mortality rates. Prophylactic strategies employing trimethoprim-sulfamethoxazole and adjunctive corticosteroids in moderate to severe cases have improved outcomes, yet emerging insights into pathogen biology and new diagnostic modalities promise further gains in early detection and tailored management.

Research from Nature Portfolio

Recent studies have revealed the genetic mechanisms underpinning antigenic variation in P. jirovecii. Detailed analysis of subtelomeric gene families indicates that individual organisms carry a repertoire of around eighty silent surface-protein genes, which undergo reassortment and mutually exclusive expression to evade host immunity. This dynamic mosaicism explains both recurrent infection in the same host and clonal spread across geographic regions.

Whole-genome assemblies of three Pneumocystis species have uncovered extensive host adaptation processes. The compact genomes lack key metabolic pathways and conventional cell-wall components such as chitin, reflecting an obligate dependence on alveolar nutrients. In parallel, expansion of surface glycoprotein superfamilies and proteases highlights specialised immune-evasion strategies. These foundational findings inform the search for novel therapeutic targets and support rational design of prophylactic interventions.

Pneumocystis Pneumonia in Immunocompromised Patients publication trend

The graph below shows the total number of articles in pneumocystis pneumonia in immunocompromised patients across all publications each year (not limited to Nature Index journals).

Technical terms

Bronchoalveolar lavage (BAL): A procedure in which fluid is instilled and recovered from a lung segment via bronchoscopy to obtain cells and pathogens for diagnosis.

Antigenic variation: The process by which a pathogen alters its surface proteins to evade host immune recognition.

CRISPR assay: A molecular diagnostic technique using clustered regularly interspaced short palindromic repeats to detect specific genetic sequences with high sensitivity.

Lactate dehydrogenase (LDH): An enzyme released into the bloodstream during tissue damage, elevated levels of which can indicate lung injury.

Alveolitis: Inflammation of the alveolar walls characterised by infiltration of immune cells, detectable on cytological examination of BAL fluid.

References

1. Fungal antigenic variation using mosaicism and reassortment of subtelomeric genes’ repertoires. Nature Communications (2023).
2. Genome analysis of three Pneumocystis species reveals adaptation mechanisms to life exclusively in mammalian hosts. Nature Communications (2016).
3. CRISPR-mediated detection of Pneumocystis transcripts in bronchoalveolar, oropharyngeal, and serum specimens for Pneumocystis pneumonia diagnosis. Journal of Clinical Investigation (2025).
4. Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Updated Guidelines From the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases (2014).
5. Pneumocystis jirovecii Pneumonia in Patients with or without AIDS, France - Volume 20, Number 9—September 2014 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases (2014).
6. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Critical Care (2018).
7. Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study. Annals of Intensive Care (2019).